Toll-like receptors (TLRs) are a key part of the innate immune system that detect pathogenassociated molecular patterns (PAMPs) of microorganisms and their stimulation results in the activation of signaling pathways leading to the modulation of inflammatory and immune responses. Since psoriasis is a complex, inflammatory and immune skin disease, characterized by an abnormal immune response and increased proliferation of keratinocytes, with an increased production of proinflammatory cytokines, TLRs could play an important role in the pathogenesis of the disease. We propose to assess the modulation of TLR expression on psoriatic skin of patients treated with Adalimumab and systemic conventional therapies. We therefore recruited fifteen patients: ten were treated with adalimumab and five with systemic conventional therapies; their clinical conditions were analyzed by PASI index and skin biopsies were evaluated for TLRI and TLRl expression by immunohistochemistry assays. Our data suggest adalimumab is not only able to improve the clinical condition of psoriatic patients, but also to modulate TLRI and TLRl expression involved in psoriasis, as in healthy skin. Adalimumab is a most promising biological drug able to orchestrate immune and inflammatory responses in psoriatic lesions, recovering TLR expression on basal keratinocytes and improving clinical conditions of psoriatic patients, with no evident side effects.
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Toll-like receptors (TLRs) are a key part of the innate immune system that detect pathogenassociated molecular patterns (PAMPs) of microorganisms and their stimulation results in the activation of signaling pathways leading to the modulation of inflammatory and immune responses. Since psoriasis is a complex, inflammatory and immune skin disease, characterized by an abnormal immune response and increased proliferation of keratinocytes, with an increased production of proinflammatory cytokines, TLRs could play an important role in the pathogenesis of the disease. We propose to assess the modulation of TLR expression on psoriatic skin of patients treated with Adalimumab and systemic conventional therapies. We therefore recruited fifteen patients: ten were treated with adalimumab and five with systemic conventional therapies; their clinical conditions were analyzed by PASI index and skin biopsies were evaluated for TLRI and TLRl expression by immunohistochemistry assays. Our data suggest adalimumab is not only able to improve the clinical condition of psoriatic patients, but also to modulate TLRI and TLRl expression involved in psoriasis, as in healthy skin. Adalimumab is a most promising biological drug able to orchestrate immune and inflammatory responses in psoriatic lesions, recovering TLR expression on basal keratinocytes and improving clinical conditions of psoriatic patients, with no evident side effects. The innate immune system senses invading organisms via pattern recognition receptors, which recognize molecular patterns shared by large groups ofpathogens. One such group ofreceptors is the Tolllike receptors (TLRs), able to activate the signalling pathway to induce the migration of the transcription factor NF-kB from the cytoplasm to the nucleus, where it binds to the promoter regions of a wide range of immune and inflammatory genes (I). There are 10 members of the TLRs family, from TLR I to TLRIO (2) (3) . In human skin, keratinocytes express TLRI, TLR2, TLR4 and TLR5 on cell surface and TLR3 and TLR9 on intracellular membranes, whereas other TLRs are expressed by Langerhans cells, dendritic cells and melanocytes (4).
Since psoriasis vulgaris (PV), a chronic, genetically determined, immune and inflammatory mediated skin disease, affecting approximately 2-3% of the Caucasian population (5) , is modulated by abnormal innate and specific immune responses and keratinocytes hyperproliferation, TLRs, in particular TLRI and TLR2, could play an important role in orchestrating inflammatory and immune responses during tissue damage and proinflammatory cytokine production (6) . PV is characterized by a strong infiltrate of T cells, neutrophils, macrophages, NK (a) (t)
Fig. 1. Immunohistochemical staining ofTLRJ in a healthy patient (a) vs lesional psoriatic skin ofa first representative untreatedpatient (b). TLRJ expression on psoriatic skin ofthe same patient treated with conventional systemic therapies evaluated three months (c) and six months after therapy (d). TLRJ expression on psoriatic skin sample ofanother patient
treated with adalimumab at time 0 (j), and on the same patient three months (g) and six months after therapy (e). Biopsies ofpsoriatic patients were taken from the same skin sites at different times oftreatment.
Fig. 2. Immunohistochemical staining ofTLR2 in a healthy patient (a) vs lesional psoriatic skin ofa second representative untreated patient (b). TLR2 expression on psoriatic skin ofthe same patient treated with conventional systemic therapies evaluated three months (c) andsix months after therapy (d). TLR2 expression on a psoriatic skin sample ofanother patient
treated with adalimumab at time 0 (j) and ofthe same patient three months (g) and six months after therapy (e). Biopsies ofpsoriatic patients were taken from the same skin sites at different times oftreatment. cells, and a type of Thl immune response, which is associated with the production of different proinflammatory cytokines, such as TNF-alpha, ILl, IL-6, IFN-gamma, IL-12, IL-17 and others, able to give rise to the psoriatic lesions and develop scaly, red or grey and thick plaques typical of PV (7) .
In this pathology, TLR expression is strongly upregulated in outer levels of psoriatic skin, whereas in healthy skin it is restricted to the basal keratinocytes, and this condition could contribute to produce high levels of proinflammatory cytokines, such as TNF-alpha, one of the major naturally occurring cytokine in the skin, which is able to interfere and exacerbate the immune and inflammatory response of psoriasis, determining the development of skin lesions (3) (4) . Previously reported data demonstrated that adalimumab, a biological drug, is an efficacious treatment for psoriatic arthritis and rheumatoid arthritis and is FDA approved for psoriasis. Adalimumab is a fully human monoclonal antibody IgG I against tumor necrosis factor alpha, which is able to interfere with the TNF-alpha activities (8) (9) (10) . We sought to characterize the pattern of innate immune receptors in psoriatic skin of patients treated or not with adalimumab, in particular TLRI and TLR2, mostly involved in psoriasis, to clarify their role and to gain further insight into the potential role of such components for new therapeutic approaches.
MATERIALS AND METHODS

Patients
Fifteen patients attending our Department of Dermatology were enrolled in the study. The subjects were of both sexes (aged from 18 to 75 years), affected with active PV without arthritis involvement and no other auto-immune and chronic diseases. Ten patients were treated with adalimumab by subcutaneous injection (40 mg/15 days) for six months and five patients were treated with systemic conventional therapies; in particular three patients received methotrexate (10 mg/ weekly m.i.) and two patients received acitretin (35 mg/day). All the subjects had been in washout of systemic conventional therapy for at least one month. RX and Mantoux assay were negative and the disease activity was evaluated by means of Psoriasis Area Severity Index (PASI) .
Biopsies were collected before and after therapy from the same sites of psoriatic lesions, and a healthy skin biopsy was used as control.
Immunohistochemistry
Serial cryostat sections (5 11m) were cut, frozen, and processed for immunohistochemistry using an HRP twostep amplified method (En Vision + TM, peroxidase, Dako Corp., Carpinteria, CA, USA), as described previously (11). Rabbit antihuman TLR I and rabbit antihuman TLR2 (R&D systems, San Jose, CA, USA) were used as primary antibodies. Diaminobenzidine and 3-amino-9-ethylcarbazolo (liquid DAB + and AEC + Substrate-Chromogen System, Dako Corp.) were used as chromogen. Negative control sections were incubated with an antihuman IgG2 mouse IgG mAb as the primary antibody.
Statistical analysis
Data were evaluated by means of the Sigma Stat 2·0 statistical software. Non-parametric Mann-Whitney U-test was used to compare patients treated with adalimumab and control groups, and Wilcoxon signed-rank test for paired data revealed differences between the two kinds of patients in response to treatments; a P-value of less than 0.05 was considered to be statistically significant.
RESULTS
PAS! evaluation
Psoriatic patients presented a strong significant progress of clinical conditions after therapy with adalimumab, showing a rapid improvement after three months of therapy (TO: 18±3.3; T3: 1.8±2.9; p = 0.002; T6: 2±4.2; p = 0.002). PASI evaluation of psoriatic patients treated with systemic conventional therapies suggests also an improvement of clinical condition, but a significant reduction of PASI score was reached only six months after treatment (TO: 17.2±4; T3: 9.2±2, p = 0.064; T6: 3.4±2.5; p 0.03).
Cutaneous expression ofTLRl and TLR2 in PV skin
Analysis of immunohistochemical staining showed high expression TLR 1 and TLR2 in PV lesions through all epidermis. As shown in Figs. I and 2 (b, c and d images), in a representative sample, a strong immunoreactivity for TLRI and TLR2 was present in upper and middle epidermis of lesional skin. However, in psoriatic skin ofthe patients treated with adalimumab, there was a significant reduction of TLR 1 and TLR2 expression on upper and middle levels of psoriatic skin, while basal keratinocytes expressed both TLRs, as shown in Figs.1 and 2 (f and g) compared to healthy skin (image a).
DISCUSSION
Adalimumab, a novel biological anti-TNF drug, is an efficacious treatment for psoriatic arthritis, rheumatoid arthritis and FDA approved for psoriasis. It is a fully human monoclonal antibody IgG 1 against tumor necrosis factor alpha, which is able to interfere with the TNF-alpha activities (14) (15) . It was seen that adalimumab is able not only to improve clinical conditions of psoriatic patients, but also to modulate TLR expression, recovering its expression as in healthy skin. In particular, it seems to down-regulate the over-expression of TLR I and TLR2 on the outer levels of psoriatic skin and to improve their expression on basal keratinocytes, as observed on healthy skin.
Alterations induced by adalimumab could be explained by the fact it is an anti-TNF and modulates the expression and activity of TLRs involved in the production of proinflammatory cytokines, including the same TNF-alpha. Thus neutralization of TNFalpha activity could alter TLR expression and its ability to activate the NF-kB signalling pathway (l2~13), which in tum regulates the transcription of immune and inflammatory genes involved in psoriatic lesions.
Furthermore, systemic conventional therapies are able to improve the clinical condition of psoriatic patients, however this improvement is slower than that in psoriatic patients treated with adalimumab. Nevertheless, systemic conventional therapies are not able to modulate TLRs, suggesting they are not able to recover the micro-environment of the healthy skin and reduce psoriatic lesions.
Adalimumab and other biological drugs seem to have a potential to reduce the side effects of many therapies that are currently used to reduce skin lesions typical of psoriasis. Further studies are necessary to identify pathological mechanisms and signalling pathways involved in this disease in order to develop new therapeutic strategies and biological drugs could be new important targets to increase more effective approaches to better the quality oflife of patients affected by autoimmune diseases, such as psoriasis vulgaris.
